Chicago, IL – January 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include, Tesla, Inc. TSLA, UnitedHealth Group Inc. UNH, Oracle Corp. ORCL and Earth Science Tech, Inc. ETST.
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Tesla, UnitedHealth and Oracle
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc., UnitedHealth Group Inc. and Oracle Corp., as well as a micro-cap stock Earth Science Tech, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Today's Featured Research Reports
Tesla shares have outperformed the Zacks Automotive - Domestic industry over the past year (+107.9% vs. +64.6%). The company’s annual deliveries contracted for the first time ever in 2024, its long-term growth story remains intact driven by its thriving Energy Generation & Storage segment, expansive Supercharger network and AI advancements.
Energy deployments doubled in 2024 and the upward trajectory is set to continue, thanks to the strong reception of its Megapack and Powerwall products. Progress in the autonomous vehicle domain, including plans to launch robotaxi services in 2025, position the company well for sustained growth.
Despite potential rebate cuts under a Trump presidency, Tesla is well-positioned to thrive without subsidies, thanks to its cost efficiency and unmatched scale. Tesla’s robust balance sheet, with a high liquidity buffer, supports continued innovation and expansion. As such, we are bullish on the stock.
(You can read the full research report on Tesla here >>>)
Shares of UnitedHealth have outperformed the Zacks Medical - HMOs industry over the past year (+1.3% vs. -2.5%). The company’s fourth-quarter earnings beat estimates. Its top line remains poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. The company’s solid health services segment provides diversification benefits.
The Government business remains well-poised for growth in the future. Adjusted net earnings per share are anticipated to be in the $29.50-$30.00 band in 2025. A sturdy balance sheet enables investments and prudent deployment of capital via share repurchases and dividend payments.
However, membership in its global business continues to be a concern. High operating costs due to rising medical expenses are hurting margins. A debt-laden balance sheet induces an increase in interest expenses.
(You can read the full research report on UnitedHealth here >>>)
Oracle shares have outperformed the Zacks Computer - Software industry over the past year (+92% vs. +15.6%). The company reported mixed fiscal Q2 2025 results, wherein earnings and revenues missed estimates. Revenues were driven by continued momentum from its Oracle Cloud Infrastructure business, including from winning cloud-computing contracts from AI-focused startups.
ORCL’s continued investment in cloud infrastructure positions it well for sustained growth in the dynamic software industry. ORCL’s partnership with Amazon for Oracle Database@AWS and general availability of Oracle Database@Google bodes well. Oracle’s Gen 2 Cloud is driving artificial intelligence clientele. Its share buybacks and dividend policy are noteworthy.
The Zacks analyst expects fiscal 2025 net sales to grow 8.7% from fiscal 2024. However, higher spending on product enhancements, toward the cloud platform amid increasing competition in the cloud domain is likely to limit margin expansion
(You can read the full research report on Oracle here >>>)
Shares of Earth Science Tech have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+270.1% vs. -10.8%). This microcap company with market capitalization of $57.69 million reported $17.1 million in revenues for the six months ended Sept. 30, 2024, driven by pharmaceutical and telemedicine subsidiaries, reflecting scalable operations and diversified revenue streams. Cash flow improved to $1.9 million from $127,910 in the prior-year period, reflecting efficiency gains.
The telemedicine platform, Peaks, positions ETST for growth amid rising virtual healthcare adoption. Strategic relocation and asset acquisitions support scaling, while RxCompound and Peaks diversify offerings and reduce market dependency, aligning with health and wellness trends.
Risks include escalating expenses, low net margins, modest cash reserves, competitive pressures, acquisition integration concerns and regulatory compliance challenges. Sustained growth depends on managing costs and leveraging innovation in telehealth.
(You can read the full research report on Earth Science Tech here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
